Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 3/20 | 0.56 |
| ▸ | LTA4H | P09960 | 4/20 | 0.55 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13172437 | 0.94 | NR5A1 (0.63) | SLC2A1LTA4HNR5A1 | |
| SCHEMBL13098201 | 0.92 | LTA4H (0.63) | SLC2A1LTA4HCYP2D6CYP1A2CYP19A1 | |
| SCHEMBL2492281 | 0.91 | LTA4H (0.53) | SLC2A1LTA4HMAPK1SMN1; SMN2 | |
| SCHEMBL13019596 | 0.87 | NR5A1 (0.56) | SLC2A1LTA4HNR5A1MAPK1SMN1; SMN2 | |
| SCHEMBL382172 | 0.87 | LTA4H (0.64) | SLC2A1LTA4HNR5A1CYP3A4MAPK1 | |
| SCHEMBL5820215 | 0.87 | LTA4H (0.64) | SLC2A1LTA4HNR5A1CYP3A4MAPK1 | |
| SCHEMBL5814534 | 0.87 | LTA4H (0.64) | SLC2A1LTA4HNR5A1CYP3A4MAPK1 | |
| SCHEMBL382629 | 0.87 | LTA4H (0.64) | SLC2A1LTA4HNR5A1CYP3A4MAPK1 | |
| SCHEMBL5819935 | 0.87 | LTA4H (0.64) | SLC2A1LTA4HNR5A1CYP3A4MAPK1 | |
| SCHEMBL4801993 | 0.87 | LTA4H (0.64) | SLC2A1LTA4HNR5A1CYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2380567-B1 | MELANIN PRODUCTION INHIBITOR | POLA CHEM IND INC (JP) | 2019-01-16 | — | — | EP | disclosed |
| EP-3009123-A1 | MELANIN PRODUCTION INHIBITOR | Pola Chemical Industries Inc. (JP) | 2016-04-20 | — | — | EP | disclosed |
| US-20150328107-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-2845587-A2 | Melanin production inhibitor | Pola Chemical Industries Inc. (JP) | 2015-03-11 | — | — | EP | disclosed |
| US-20140363389-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-8846012-B2 | Melanin production inhibitor | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-09-30 | — | — | US | disclosed |
| EP-2380567-A1 | MELANIN PRODUCTION INHIBITOR | Pola Chemical Industries Inc. (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | TYR, F12, TH | SLC2A1 3636/4885LTA4H 1800/4885NR5A1 2246/4885 |
| US-20150328107-A1 | MELANIN PRODUCTION INHIBITOR | TYR, MC1R, F12 | SLC2A1 3517/4885LTA4H 1612/4885NR5A1 2281/4885 |
| US-20140363389-A1 | MELANIN PRODUCTION INHIBITOR | TYR, F12, MC1R | SLC2A1 3586/4885LTA4H 1762/4885NR5A1 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.